| Literature DB >> 33419316 |
Benoît Bataille1, Bennadji Raoudha1, Florence Le Tinier1, Laurent Basson1, Alexandre Escande1, Hélène Langin1, Emmanuelle Tresch2, Frederik Crop3, Franck Darloy4, Damien Carlier4, Eric Lartigau1,5, David Pasquier1,5.
Abstract
The objective of this study was to evaluate the acute and medium-term toxicities, the quality of life, and aesthetic results of patients with breast cancer (BC) treated with tomotherapy. This was a prospective study, including patients with BC treated by tomotherapy. Radiation therapy delivered 50 Gy in 25 fractions to the breast or chest wall and to lymph node areas, with a simultaneous integrated boost at a dose of 60 Gy at the tumor bed in cases of breast conservative surgery. We included 288 patients, 168 and 120 treated with breast-conserving surgery and mastectomy respectively. Two hundred sixty patients (90.3%) received lymph node irradiation. Median follow-up was 25 months (6-48). Acute dermatitis was observed in 278 patients (96.5%), mostly grade 1 (59.7%). The aesthetic aspect of the breast at one year was reported as "good" or "excellent" in 84.6% of patients. The patients' quality of life improved over time, especially those treated with chemotherapy. The two-year overall survival and disease-free survival were 97.8% (95% confidence interval (CI): 94.1-99.2%), and 93.4% (95% CI: 89.2-96.0%) respectively. Tomotherapy for locally advanced BC has acceptable toxicity, supporting its use in this indication; however, longer follow-up is needed to assess long-term outcomes.Entities:
Keywords: IMRT; breast cancer; quality of life; simultaneous integrated boost; tomotherapy
Year: 2020 PMID: 33419316 PMCID: PMC7766204 DOI: 10.3390/cancers12123852
Source DB: PubMed Journal: Cancers (Basel) ISSN: 2072-6694 Impact factor: 6.639